Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 7, Issue 5, Pages 1550-1559Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2019.01.022
Keywords
Allergy; Food allergy; Oral immunotherapy; Peanut allergy; Mindsets; Patient experience; Allergic symptoms; Pediatric allergy
Categories
Funding
- National Institutes of Health/National Center for Complementary and Integrative Health [DP2AT009511]
- Foundation for the Science of the Therapeutic Encounter
- Naddisy Foundation
- FARE Center of Excellence
- National Institute of Allergy and Infectious Diseases
- Sean N. Parker Foundation for Allergy and Asthma Research
- Shaper Family Stanford Interdisciplinary Graduate Fellowship
- Stanford Interdisciplinary Graduate Fellowship
Ask authors/readers for more resources
BACKGROUND: Oral immunotherapy (OIT) can lead to desensitization to food allergens, but patients can experience treatment-related symptoms of allergic reactions that cause anxiety and treatment dropout. Interventions to improve OIT for patients are needed. OBJECTIVE: To determine whether fostering the mindset that nonelife-threatening symptoms during OIT can signal desensitization improves treatment experience and outcomes. METHODS: In a randomized, blinded, controlled phase II study, 50 children/adolescents (28% girls, aged 7-17 years, M =10.82, standard deviation =3.01) completed 6-month OIT for peanut allergies. Patients and their parent(s) had monthly clinic visits at the Sean N. Parker Center for Allergy and Asthma Research between January 5, 2017, and August 3, 2017. All families received identical symptommanagement training. In a 1: 1 approach, 24 patients and their families were informed that nonelife-threatening symptoms during OIT were unfortunate side effects of treatment, and 26 patients and their families were informed that nonelife-threatening symptoms could signal desensitization. Families participated in activities to reinforce these symptom mindsets. RESULTS: Compared with families informed that symptoms are side effects, families informed that symptoms can signal desensitization were less anxious (B = -0.46, 95% confidence interval [CI]: L0.76 to L0.16; P <.003), less likely to contact staff about symptoms (5/24 [9.4%] vs 27/154 [17.5%] instances; P = .036), experienced fewer nonelife-threatening symptoms as doses increased (B-Interaction = -0.54, 95% CI: L0.83 toL0.27; P <.001), less likely to skip/reduce doses (1/26 [4%] vs 5/24 [21%] patients; P < .065), and showed a greater increase in patient peanut-specific blood IgG4 levels (B-Interaction [0.76, 95% CI: 0.36 to 1.17; P <.001). CONCLUSIONS: Fostering the mindset that symptoms can signal desensitization improves OIT experience and outcomes. Changing how providers inform patients about nonelifethreatening symptoms is a promising avenue for improving treatment. (C) 2019 American Academy of Allergy, Asthma & Immunology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available